Long-term Observational Study to Evaluate the DFS and OS of Adjuvant FOLFIRINOX Regimen in Pancreatic Cancer Patients

HK inno.N

Status: Enrolling

Conditions: Adjuvant Chemotherapy

Study type: Observational

Funder types: Industry

Identifiers

NCT06389552

IN_CTP_N01

Details and patient eligibility

About

This study is designed to evaluate the safety and efficacy of adjuvant FOLFIRINOX regimen in pancreatic cancer patients after curative surgery.

Full description

This study is multi-center, prospective, long-term follow-up observational study.

Enrollment: 36 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age over 19 at the time of obtaining the informed consent form
• Planning to FOLFIRINOX as adjuvant therapy after pancreatic cancer surgery
• ECOG 0 or 1
• Scheduled to RO or R1 resection
• Organ function capable of chemotherapy

Exclusion criteria

• FOLFIRINOX contraindications among the drug approval requirements
• Palliative Therapy
• Experienced toxic reactions or Hypersensitivity reactions of FOLFIRINOX